Replies to post #110570 on Biotech Values

[DewDiligence]

While the trial results of M118 looked promising, did you think the results were at a level where you'd dump huge sums of money into?

If not for the prospect of generic Angiomax in a few years, my answer would be a clear yes because a safe and reversible “upstream” agent in ACS is a large unmet need. However, the relentless cost pressure on hospital-oriented drugs lessens the business proposition for M118 insofar as it’s highly likely a generic version of Angiomax will reach the US market before M118 could gain any traction.